[
  {
    "ts": null,
    "headline": "AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE",
    "summary": "Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
    "url": "https://finnhub.io/api/news?id=a312cb59f2e6b4365fba7f5c1d6461a82ead66fd6ef3cfda28ac2b0842cf7584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749153660,
      "headline": "AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE",
      "id": 135066830,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.",
      "url": "https://finnhub.io/api/news?id=a312cb59f2e6b4365fba7f5c1d6461a82ead66fd6ef3cfda28ac2b0842cf7584"
    }
  },
  {
    "ts": null,
    "headline": "Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact",
    "summary": "Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why I maintain a Hold rating on VIGL.",
    "url": "https://finnhub.io/api/news?id=f6436b9411c6343e51b9eaee1e6569e8dde0a50545141d23a648385c2c4e8a9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749144644,
      "headline": "Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact",
      "id": 135065389,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214942377/image_2214942377.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why I maintain a Hold rating on VIGL.",
      "url": "https://finnhub.io/api/news?id=f6436b9411c6343e51b9eaee1e6569e8dde0a50545141d23a648385c2c4e8a9d"
    }
  },
  {
    "ts": null,
    "headline": "RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar",
    "summary": "Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.",
    "url": "https://finnhub.io/api/news?id=0489cb5bef62a32f0300782d7fef4d4262f8204c2fe75cb5c6f9e7e9f80e39b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749137280,
      "headline": "RDY & ALVO Ink Collaboration Deal for Merck's Keytruda Biosimilar",
      "id": 135063552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Dr. Reddy teams up with Alvotech to co-develop and commercialize a biosimilar of MRK's Keytruda, aiming to expand its biosimilars footprint.",
      "url": "https://finnhub.io/api/news?id=0489cb5bef62a32f0300782d7fef4d4262f8204c2fe75cb5c6f9e7e9f80e39b2"
    }
  },
  {
    "ts": null,
    "headline": "Dow up 125 points on gains for shares of Amazon.com Inc., Salesforce",
    "summary": "Dow up 125 points on gains for shares of Amazon.com Inc., Salesforce",
    "url": "https://finnhub.io/api/news?id=aa88338a15de6d8bf4c02f26a72c1fa5340af7f1a7685b57c3dc74d2b9f20871",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749122280,
      "headline": "Dow up 125 points on gains for shares of Amazon.com Inc., Salesforce",
      "id": 135048299,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow up 125 points on gains for shares of Amazon.com Inc., Salesforce",
      "url": "https://finnhub.io/api/news?id=aa88338a15de6d8bf4c02f26a72c1fa5340af7f1a7685b57c3dc74d2b9f20871"
    }
  },
  {
    "ts": null,
    "headline": "Samsung Bioepis Secures Marketing Approval In Korea For Its Biosimilar To Amgen's Bone Cancer Drug Xgeva",
    "summary": "Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen's bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors...",
    "url": "https://finnhub.io/api/news?id=0976209e25cae895b2b9ea7047afeb59c937a596856039b4b4c76a1c3762cd2b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749111191,
      "headline": "Samsung Bioepis Secures Marketing Approval In Korea For Its Biosimilar To Amgen's Bone Cancer Drug Xgeva",
      "id": 135045176,
      "image": "",
      "related": "AMGN",
      "source": "Finnhub",
      "summary": "Samsung Bioepis Co., Ltd. has secured marketing approval in Korea for XBRYK, its biosimilar to Amgen's bone cancer drug XGEVA, used to prevent fractures in those with bone metastases from solid tumors...",
      "url": "https://finnhub.io/api/news?id=0976209e25cae895b2b9ea7047afeb59c937a596856039b4b4c76a1c3762cd2b"
    }
  }
]